On December 24, the Toumai^® laparoscopic surgical robot successfully completed its 100th commercial installation at Hospital Unimed Foz do Iguaçu in Brazil. This milestone marks Toumai^® as the first—and currently the only—Chinese surgical robot brand to achieve 100 commercial installations worldwide.

Reaching this milestone signifies a comprehensive advancement of the Toumai^® robotic system across key dimensions, including quality and regulatory compliance, scalable manufacturing capability, engineering and system validation, global delivery capacity, clinical adaptability, and end-to-end service support, ushering the platform into a new stage of development.

To date, Toumai^® has recorded more than 160 global orders. Across the MicroPort^® MedBot Group’s core product lines—including laparoscopic, orthopedic, and vascular interventional robotics—total cumulative orders have exceeded 230 units, with more than 150 systems commercially installed, underscoring the Group’s steadily strengthening commercialization capabilities.

Notably, within just over two months—from October to December—Toumai^® progressed from surpassing 100 orders to exceeding 160 orders, setting a new record for the commercialization pace of Chinese surgical robot brands.

In China, Toumai^® continues to secure placements in leading top-tier public hospitals, while also achieving multiple breakthroughs in the high-end private healthcare sector, with its clinical applications expanding steadily. In the international market, its commercialization footprint now spans more than 40 countries and regions across Asia, Europe, Oceania, and Latin America. Among these, 15 countries have achieved multi-unit sales with installations across multiple hospitals, forming the most extensive and deeply established global application network to date for a Chinese-manufactured laparoscopic surgical robot.

The milestone of 100 commercial installations represents not merely a numerical achievement, but a strong testament to Toumai^®’s global clinical trust, industrial maturity, and system-level capabilities. Advancing along a replicable and sustainable commercialization pathway, Toumai^® is steadily expanding its global footprint—empowering surgeons worldwide and delivering higher-quality minimally invasive treatment options for patients.